Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe. - Wikidata - wikimedia - TriplyDB

Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.

Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.

http://www.wikidata.org/entity/Q33638491

about

Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs.Healthcare providers' perspectives on the acceptability and uptake of HPV vaccines in Zimbabwe.Genotypic diversity of anogenital human papillomavirus in women attending cervical cancer screening in Harare, Zimbabwe.Cervical cancer in Zimbabwe: a situation analysis.

P2860

Q35141881-148E9A98-1E1D-4885-8DCE-C359A5BE60D9 Q38378953-508BAD91-A23E-48EF-ACF2-CF76B6305D11 Q38846847-646DE88F-E52C-4CB5-9572-5373A7036C07 Q41990954-0AFD2A5D-5F82-43CB-8A96-2DCFA3C36685

P2860

Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.

http://www.wikidata.org/entity/Q33638491

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.

@ast

Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.

@en

type

label

Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.

@ast

Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.

@en

prefLabel

Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.

@ast

Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.

@en

P1433

Q33638491-69B79813-90DC-49B9-9013-65901E174121

P1476

Q33638491-97589F63-ED2E-49EB-8DAE-6E97CB3B4B9F

P2093

Q33638491-2B4256BE-45C7-4628-BA65-B06D9EF034D4

Q33638491-D28E3C4C-1837-43C0-A93A-F105D741B2D8

Q33638491-DB026C97-7EE7-43EE-9556-F8667F4A3272

Q33638491-DB4FFC32-9DE0-4456-835C-4D281EB49954

P2860

Q33638491-01F40EEC-FEA1-44E4-BFF6-7FE033F2626B

Q33638491-07DEFD32-6E12-4E3F-B293-3BA8EB93F753

Q33638491-16A79E07-9E92-4197-9465-43C659803FF8

Q33638491-1CF94711-9A5C-4403-B178-DE9ABCA172E8

Q33638491-212E6BA7-D117-4449-9EDC-C554423E7D49

Q33638491-2752DFA0-7AA5-46B4-BAF8-EDC24F6EBB65

Q33638491-2FEB23BE-099F-49ED-B57B-F1B15E6A3567

Q33638491-42CA8492-5A19-4123-BDD1-CFE73FA3D545

Q33638491-462CAB87-C414-48BA-B4E8-06E3C3B94A12

Q33638491-47A2B8DF-973A-419C-9C1D-BD060A70FE08

P2888

Q33638491-5DF57AD9-1CA1-4319-8459-A38D2258F98D

P304

Q33638491-D57E9CAD-916C-4D7A-8254-E19E1A4A73C4

P31

Q33638491-69FC4417-B925-4793-80E9-2BA1084FD082

P356

Q33638491-BA9EB108-EED3-4B0F-AAA5-68D021315719

P478

Q33638491-CF128536-007D-4D24-BE6A-5B7F023CD633

P577

Q33638491-A76DDB93-3D40-4794-B741-030ACCD657A1

P5875

Q33638491-1FD7A384-501A-4240-A85D-79264E238683

P6179

Q33638491-CC07ADDB-F7EB-423F-A531-547E273BAA8C

P698

Q33638491-E77DBE71-68C5-4432-BF89-26FBFDB02DA5

P921

Q33638491-4523AEE8-39CA-45D6-A4B2-055D50FB4FEE

P932

Q33638491-65AE4E6A-1212-4B6F-887A-584FC0D21CA7

P356

P1433

Infectious Agents and Cancer

P1476

Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.

@en

P2093

Hilda T Matarira

http://www.w3.org/2001/XMLSchema#string

Natasha L Sebata

http://www.w3.org/2001/XMLSchema#string

Nyasha Chin'ombe

http://www.w3.org/2001/XMLSchema#string

Vurayai Ruhanya

http://www.w3.org/2001/XMLSchema#string

P2860

The causal relation between human papillomavirus and cervical cancer.

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

Papillomaviruses and cancer: from basic studies to clinical application

Epidemiologic classification of human papillomavirus types associated with cervical cancer

Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review.

Epidemiology of HPV in HIV-positive and HIV-negative fertile women in Cameroon, West Africa.

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis.

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

P2888

P304

16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1750-9378-9-16

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262532586

http://www.w3.org/2001/XMLSchema#string

P6179

1036630319

http://www.w3.org/2001/XMLSchema#string

P698

24847377

http://www.w3.org/2001/XMLSchema#string

P921

P932

4028280

http://www.w3.org/2001/XMLSchema#string